Monitoring and Evaluation Study of Project ECHO for ILD

The study will utilize pre-post survey measures to evaluate Project ECHO for ILD with respect to an initial set of practice and clinical outcomes and relies on questionnaire data obtained from providers participating in Project ECHO for ILD at baseline, at 6 months, and at study end.

Study Overview

• Status: Enrolling by invitation
• Conditions: Interstitial Lung Diseases

Detailed Description

Project ECHO (Extension for Community Healthcare Outcomes) is a knowledge-sharing model to expand the capacity of the health care workforce so that more people can get high quality care for their health conditions in or near the communities where they live. The model brings specialty disease expertise to community providers through its hub-and-spoke networks. The model relies on videoconferencing to connect local providers in non-urban or underserved communities (spoke sites) with an interdisciplinary team of specialist providers at academic medical centers (hubs) during virtual "teleECHO" clinic sessions, which include brief educational lectures and case-based, experiential learning. It is a guided, technology-enabled collaborative practice model in which community providers become experts in an area of community need within the scope of their practice, operating with increasing independence as their skills and self-efficacy grow. The model establishes meaningful, ongoing relationships with hub specialists who serve as telementors for spoke providers and relies on case-based learning from presentations of real-world de-identified patient cases.

The overarching goal of the project is to implement and evaluate an adaptation of the ECHO model to interstitial lung disease (ILD) diagnosis and care among primary care physicians (PCPs) and community pulmonologists in non-urban or underserved communities.

• Study Type: Observational
• Enrollment (Anticipated): 200

Contacts and Locations

Study Locations

• United States
  • Massachusetts
    • Boston, Massachusetts, United States, 02130
      • Pulmonary Care and Research Collaborative, Ltd.

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Pulmonologists and primary care physicians who participate in Project ECHO for ILD.

Description

Inclusion Criteria:

• Pulmonologists and primary care physicians who participate in Project ECHO for ILD.

Exclusion Criteria:

-

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Impact on procedural knowledge	Change in participants' skills or competence in knowing ILD testing and treatment procedures based on a Likert scale rating (1=no skill and 7=expert, teach other) included in the structured participant surveys administered at baseline, 6 months, and at study end.	Up to 18 months
Impact on local care utilization	Change of proportion of patients utilizing local ILD care services, including the frequency of local follow-up visits and testing. Change in scores will be calculated between structured participant surveys responses at baseline, 6 months, and at study end.	Up to 18 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Time to ILD diagnosis	The amount of time it takes for a participant's patient to be given an established, named ILD diagnosis (IPAF, IPF, HP, CTD-ILD, myositis-ILD, idiopathic NSIP, etc.) from onset of respiratory symptoms and from the time of first pulmonologist appointment. This data will be obtained from teleECHO clinic management records and participants' case and follow-up reporting for patients who were presented to the ECHO for diagnosis.	Up to 18 months
Content expert facilitation	Proportion of participants who agree that the quality of content expert facilitation was adequate during the teleECHO session. This will be collected monthly from post-session surveys via a Likert scale (1=strongly disagree and 5=strongly agree).	Up to 18 months

Collaborators and Investigators

• Sponsor: Pulmonary Care and Research Collaborative Limited
• Collaborators: Genentech, Inc.
• Investigators: Principal Investigator: Aliaa Barakat, PhD, Pulmonary Care and Research Collaborative, Ltd.

Study record dates

Study Major Dates

• Study Start (Anticipated): July 1, 2022
• Primary Completion (Anticipated): December 1, 2023
• Study Completion (Anticipated): March 1, 2024

Study Registration Dates

• First Submitted: June 30, 2022
• First Submitted That Met QC Criteria: July 7, 2022
• First Posted (Actual): July 13, 2022

Study Record Updates

• Last Update Posted (Actual): July 13, 2022
• Last Update Submitted That Met QC Criteria: July 7, 2022
• Last Verified: July 1, 2022

More Information

Terms related to this study

• Keywords: Sarcoidosis; Idiopathic Pulmonary Fibrosis; Hypersensitivity Pneumonitis; Pulmonary Fibrosis; Progressive Fibrosing Interstitial Lung Disease; Interstitial Lung Disease Associated With Systemic Sclerosis; Myositis-Associated Interstitial Lung Disease
• Additional Relevant MeSH Terms: Respiratory Tract Diseases; Lung Diseases; Lung Diseases, Interstitial
• Other Study ID Numbers: ILDC-002

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No